LOMEFLOXACIN CLINICAL PHARMACOKINETICS

被引:15
作者
FREEMAN, CD
NICOLAU, DP
BELLIVEAU, PP
NIGHTINGALE, CH
机构
[1] HARTFORD HOSP,OFF RES,80 SEYMOUR ST,HARTFORD,CT 06115
[2] HARTFORD HOSP,DEPT PHARM,HARTFORD,CT 06115
[3] UNIV CONNECTICUT,SCH PHARM,STORRS,CT 06268
关键词
D O I
10.2165/00003088-199325010-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lomefloxacin is a quinolone antibiotic with chemical and microbiological properties similar to most commercially available agents of this class. There are differences, however, between lomefloxacin and other quinolones in activity against specific micro-organisms, a situation that is typical of most antibiotic classes. The pharmacokinetics of lomefloxacin support once- or twice-daily dosage, depending on the pathogen or site of infection. This is a result of its relatively high serum concentrations and long half-life. The outstanding pharmacokinetic features of lomefloxacin are its high degree of tissue distribution, lack of significant metabolism (and, therefore, no competitive drug interactions with other metabolised drugs showing a common metabolic pathway), and good oral absorption. Like most fluoroquinolones, lomefloxacin can chelate with heavy metals. However, this interaction can be eliminated by administering lomefloxacin 2h before the cation-containing products. Dosage adjustments are required in patients with renal dysfunction. However, patients with liver disease do not require alterations in lomefloxacin dosage regimens. The safety profile, lack of significant drug interactions and convenience of administration make lomefloxacin a useful agent in specific clinical settings.
引用
收藏
页码:6 / 19
页数:14
相关论文
共 110 条
[1]   STRUCTURE-EPILEPTOGENICITY RELATIONSHIP OF QUINOLONES WITH SPECIAL REFERENCE TO THEIR INTERACTION WITH GAMMA-AMINOBUTYRIC ACID RECEPTOR-SITES [J].
AKAHANE, K ;
SEKIGUCHI, M ;
UNE, T ;
OSADA, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (10) :1704-1708
[2]   CONCENTRATIONS OF ORAL LOMEFLOXACIN IN SERUM AND BRONCHIAL-MUCOSA [J].
BALDWIN, DR ;
HONEYBOURNE, D ;
ANDREWS, JM ;
ASHBY, JP ;
WISE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1017-1019
[3]  
BERGOGNEBEREZIN E, 1992, AM J MED S4A, V92, pS12
[4]   COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].
BLASER, J ;
STONE, BB ;
GRONER, MC ;
ZINNER, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060
[5]   PHARMACOKINETICS OF LOMEFLOXACIN IN RENALLY COMPROMISED PATIENTS [J].
BLUM, RA ;
SCHULTZ, RW ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (12) :2364-2368
[6]   INFLUENCE OF RENAL-FUNCTION ON THE PHARMACOKINETICS OF LOMEFLOXACIN COMPARED WITH OTHER FLUOROQUINOLONES [J].
BLUM, RA .
AMERICAN JOURNAL OF MEDICINE, 1992, 92 :S18-S21
[7]   CHARACTERIZATION OF MECHANISMS OF QUINOLONE RESISTANCE IN PSEUDOMONAS-AERUGINOSA STRAINS ISOLATED INVITRO AND INVIVO DURING EXPERIMENTAL ENDOCARDITIS [J].
CHAMBERLAND, S ;
BAYER, AS ;
SCHOLLAARDT, T ;
WONG, SA ;
BRYAN, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (05) :624-634
[8]   ANTIMICROBIAL EFFECTS OF LOMEFLOXACIN INVITRO [J].
CHAMBERS, ST ;
PEDDIE, BA ;
ROBSON, RA ;
BEGG, EJ ;
BOSWELL, DR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (04) :481-489
[9]   INVITRO ACTIVITY OF LOMEFLOXACIN (SC-47111-NY-198), A DIFLUOROQUINOLONE 3-CARBOXYLIC ACID, COMPARED WITH THOSE OF OTHER QUINOLONES [J].
CHIN, NX ;
NOVELLI, A ;
NEU, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :656-662
[10]  
CHRIST W, 1989, REV INFECT DIS, V11, pS1393